UK ranks 22nd out of 29 comparable countries for survival of Brain Cancer
NW Biotherapeutics, maker of DC Vax to treat glioblastoma — applied for approval in the UK.
Read more
Experimental GBM treatment — DC Vax — is hoped to be moving forward in the UK
NW Biotherapeutics, maker of DC Vax to treat glioblastoma — applied for approval in the UK.